Tencent invests in RNA innovative drug R&D company Hongxin Bio
December 11, 2025
Source: drugdu
34
Shenzhen Hongxin Biotechnology Co., Ltd. recently underwent industrial and commercial registration changes, adding Guangxi Tencent Venture Capital Co., Ltd. and others as shareholders, while its registered capital increased to 2.55739 million yuan. Qichacha information shows that the company was established in 2021, and its business scope includes: biomass energy technology services; medical research and experimental development; cell technology research and application, etc. According to its official website, Hongxin Biotechnology is an RNA innovative drug company.Research and development company.
https://finance.eastmoney.com/a/202512113588542497.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- U.S. ERs Are Failing Sickle Cell Patients In Pain, Study Says December 11, 2025
- GLP-1 Medications Show Little Effect on Cancer, Study Shows December 11, 2025
- Qilu Pharmaceutical wins blockbuster new drug December 11, 2025
- Originating from traditional Chinese medicine, it defeated dapagliflozin head-to-head December 11, 2025
- Juncell Therapeutics Submits Hong Kong Listing Application, with CITIC Securities as Sole Sponsor December 11, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
